Update on Survival in Osteosarcoma

Orthopedic Clinics of North America

Volumn 47, Issue 1, 2016, Pages 283-292

  Anderson, Megan E ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Late effects; Limb salvage surgery; Osteosarcoma; Prognosis; Survival; Systemic chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IFOSFAMIDE; METHOTREXATE; MIFAMURTIDE;

ABOVE KNEE AMPUTATION; AGE; ALOPECIA; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER GRADING; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CANCER SURVIVOR; CARDIOTOXICITY; CONGESTIVE HEART FAILURE; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERABILITY; HEART FAILURE; HUMAN; KIDNEY FAILURE; LIMB SALVAGE; LUNG NODULE; LUNG SURGERY; METASTASIS; METASTASIS RESECTION; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROTOXICITY; OSTEOSARCOMA; OTOTOXICITY; OVERALL SURVIVAL; PATHOLOGIC FRACTURE; PRIORITY JOURNAL; REVIEW; SECOND CANCER; SYSTEMIC THERAPY; TUMOR VOLUME; BONE NEOPLASMS; MORTALITY; PLASTIC SURGERY; PROGNOSIS; SECONDARY; SURVIVAL; TUMOR RECURRENCE;

BONE NEOPLASMS; HUMANS; LIMB SALVAGE; NEOPLASM RECURRENCE, LOCAL; OSTEOSARCOMA; PROGNOSIS; RECONSTRUCTIVE SURGICAL PROCEDURES; SURVIVAL ANALYSIS;

EID: 84961798956     PISSN: 00305898     EISSN: 15581373     Source Type: Journal    
DOI: 10.1016/j.ocl.2015.08.022     Document Type: Review

References (60)

1. Meyers P.A., Schwartz C.L., Krailo M., et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 2005, 23:2004-2011.
2. Ferrari S., Meazza C., Palmerini E., et al. Nonmetastatic osteosarcoma of the extremity. Neoadjuvant chemotherapy with methotrexate, cisplatin, doxorubicin and ifosfamide. An Italian Sarcoma Group study (ISG/OS-Oss). Tumori 2014, 100:612-619.
3. Anninga J.K., Gelderblom H., Fiocco M., et al. Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand?. Eur J Cancer 2011, 47:2431-2445.
4. Allison D.C., Carney S.C., Ahlmann E.R., et al. A meta-analysis of osteosarcoma outcomes in the modern medical era. Sarcoma 2012, 2012:704872.
5. Available at:. Accessed June 17, 2015. http://nccd.cdc.gov/USCS/childhoodcancerdetailedbyICCC.aspx.
6. Rosenberg A.E., Cleton-Jansen A.-M., de Pinieux G., et al. Conventional osteosarcoma. WHO classification of tumours of soft tissue and bone 2013, 282. IARC, Lyon (France). 4th edition. C.D.M. Fletcher, J.A. Bridge, P.C.W. Hogendoorn (Eds.).
7. Heath F.A. Osteo-sarcoma of the femur and lung. Br Med J 1877, 2(887):921.
8. Duchman K.R., Gao Y., Miller B.J. Prognostic factors for survival in patients with high-grade osteosarcoma using the Surveillance, Epidemiology, and End Results (SEER) Program database. Cancer Epidemiol 2015, 39(4):593-599.
9. Bruland O.S., Høifødt H., Saeter G., et al. Hematogenous micrometastases in osteosarcoma patients. Clin Cancer Res 2005, 11:4666-4673.
10. Kager L., Zoubek A., Potschger U., et al. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol 2003, 21:2011-2018.
11. Rosen G., Marcove R.C., Huvos A.G. Primary osteogenic sarcoma: eight-year experience with adjuvant chemotherapy. J Cancer Res Clin Oncol 1983, 106(Suppl):55-67.
12. Eilber F., Giuliano A., Eckardt J., et al. Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. J Clin Oncol 1987, 5:21-26.
13. Bernthal N.M., Federman N., Eilber F.R., et al. Long-term results (>25 years) of a randomized, prospective clinical trial evaluating chemotherapy in patients with high-grade, operable osteosarcoma. Cancer 2012, 118:5888-5893.
14. Link M.P., Goorin A.M., Horowitz M., et al. Adjuvant chemotherapy of high-grade osteosarcoma of the extremity. Updated results of the Multi-Institutional Osteosarcoma Study. Clin Orthop Relat Res 1991, 270:8-14.
15. Link M.P., Goorin A.M., Miser A.W., et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 1986, 314:1600-1606.
16. Rosen G. Preoperative (neoadjuvant) chemotherapy for osteogenic sarcoma: a ten year experience. Orthopedics 1985, 8:659-664.
17. Slade A.D., Warneke C.L., Hughes D.P., et al. Effect of concurrent metastatic disease on survival in children and adolescents undergoing lung resection for metastatic osteosarcoma. J Pediatr Surg 2015, 50:157-160.
18. Briccoli A., Rocca M., Salone M., et al. High grade osteosarcoma of the extremities metastatic to the lung: long-term results in 323 patients treated combining surgery and chemotherapy, 1985-2005. Surg Oncol 2010, 19:193-199.
19. Salah S., Toubasi S. Factors predicting survival following complete surgical remission of pulmonary metastases in osteosarcoma. Mol Clin Oncol 2015, 3:157-162.
20. Gelderblom H., Jinks R.C., Sydes M., et al. Survival after recurrent osteosarcoma: data from 3 European Osteosarcoma Intergroup (EOI) randomized controlled trials. Eur J Cancer 2011, 47:895-902.
21. Bielack S., Jurgens H., Jundt G., et al. Osteosarcoma: the COSS experience. Cancer Treat Res 2009, 152:289-308.
22. Berner K., Hall K.S., Monge O.R., et al. Prognostic factors and treatment results of high-grade osteosarcoma in Norway: a scope beyond the "classical" patient. Sarcoma 2015, 2015:516843.
23. Bacci G., Bertoni F., Longhi A., et al. Neoadjuvant chemotherapy for high-grade central osteosarcoma of the extremity. Histologic response to preoperative chemotherapy correlates with histologic subtype of the tumor. Cancer 2003, 97:3068-3075.
24. Hauben E.I., Weeden S., Pringle J., et al. Does the histologic subtype of high-grade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival? A study on 570 patients of two consecutive trials of the European Osteosarcoma Intergroup. Eur J Cancer 2002, 38:1218-1225.
25. Song W.S., Kong C.B., Jeon D.G., et al. Prognosis of extremity osteosarcoma in patients aged 40-60 years: a cohort/case controlled study at a single institute. Eur J Surg Oncol 2010, 36:483-488.
26. Longhi A., Errani C., Gonzales-Arabio D., et al. Osteosarcoma in patients older than 65 years. J Clin Oncol 2008, 26:5368-5373.
27. Harting M.T., Lally K.P., Andrassy R.J., et al. Age as a prognostic factor for patients with osteosarcoma: an analysis of 438 patients. J Cancer Res Clin Oncol 2010, 136:561-570.
28. Shaylor P.J., Peake D., Grimer R.J., et al. Paget's osteosarcoma-no cure in sight. Sarcoma 1999, 3:191-192.
29. Mankin H.J., Hornicek F.J. Paget's sarcoma: a historical and outcome review. Clin Orthop Relat Res 2005, 438:97-102.
30. Luetke A., Meyers P.A., Lewis I., et al. Osteosarcoma treatment-Where do we stand? A state of the art review. Cancer Treat Rev 2014, 40:523-532.
31. Benjamin R.S., Patel S.R. Pediatric and adult osteosarcoma: comparisons and contrasts in presentation and therapy. Cancer Treat Rev 2009, 152:355-363.
32. Collins M., Wilhelm M., Conyers R., et al. Benefits and adverse events in younger versus older patients receiving neoadjuvant chemotherapy for osteosarcoma: findings from a meta-analysis. J Clin Oncol 2013, 31:2303-2312.
33. Su W., Lai Z., Wu F., et al. Clinical efficacy of preoperative chemotherapy with or without ifosfamide in patients with osteosarcoma of the extremity: meta-analysis of randomized controlled trials. Med Oncol 2015, 32:481.
34. Xiao X., Wang W., Wang Z. The role of chemotherapy for metastatic, relapsed, and refractory osteosarcoma. Pediatr Drugs 2014, 16:503-512.
35. Whelan J.S., Bielack S.S., Marina N., et al. EURAMOS-1, an international randomized study for osteosarcoma: results from pre-randomisation treatment. Ann Oncol 2015, 26:407-414.
36. Saumet L., Deschamps F., Marec-Berard P., et al. Radiofrequency ablation of metastases from osteosarcoma in patients under 25 years: the SCFE experience. Pediatr Hematol Oncol 2015, 32:41-49.
37. Hawkins D.S., Arndt C.A. Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy. Cancer 2003, 98:2447-2456.
38. Ferrari S., Briccoli A., Mercuri M., et al. Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival. J Clin Oncol 2003, 21:710-715.
39. Daw N.C., Chou A.J., Jaffe N., et al. Recurrent osteosarcoma with a single pulmonary metastasis: a multi-institutional review. Br J Cancer 2015, 112:278-282.
40. Enneking W.F., Spanier S.S., Goodman M.A. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res 1980, 153:103-120.
41. Bus M.P., Bramer J.A., Schaap G.R., et al. Hemicortical resection and inlay allograft reconstruction for primary bone tumors: a retrospective evaluation in the Netherlands and review of the literature. J Bone Joint Surg Am 2015, 97:738-750.
42. Hawkins D.S., Conrad E.U., Butrynski J.E., et al. [F-18]-flurordeoxy-D-glucose-positron emission tomography response is associated with outcome for extremity osteosarcoma in children and young adults. Cancer 2009, 115:3519-3525.
43. Byun B.H., Kong C.B., Lim I., et al. Combination of 18F-FDG PET/CT and diffusion-weighted MR imaging as a predictor of histologic response to neoadjuvant chemotherapy: preliminary results in osteosarcoma. J Nucl Med 2013, 54:1053-1059.
44. Li J., Wang Z., Guo Z., et al. Precise resection and biological reconstruction under navigation guidance for young patients with juxta-articular bone sarcoma in lower extremity: preliminary report. J Pediatr Orthop 2014, 34:101-108.
45. Jeys L., Matharu G.S., Nandra R.S., et al. Can computer-assisted surgery reduce the risk of an intralesional margin and reduce the rate of local recurrence in patients with a tumour of the pelvis or sacrum?. Bone Joint J 2013, 95-B:1417-1424.
46. Reddy K.I., Wafa H., Gaston C.L., et al. Does amputation offer any survival benefit over limb salvage in osteosarcoma patients with poor chemonecrosis and close margins?. Bone Joint J 2015, 97-B:115-120.
47. Bertrand T.E., Cruz A., Binitie O., et al. Do surgical margins affect local recurrence and survival in extremity, nonmetastatic, high-grade osteosarcoma?. Clin Orthop Relat Res 2015, [Epub ahead of print].
48. Abudu A., Sferopoulous N.K., Tillman R.M., et al. The surgical treatment and outcome of pathological fractures in localised osteosarcoma. J Bone Joint Surg Br 1996, 78:694-698.
49. Jaffe N., Spears R., Eftekhari F., et al. Pathologic fracture in osteosarcoma. Impact of chemotherapy on primary tumor and survival. Cancer 1987, 59:701-709.
50. Bacci G., Ferrari S., Longhi A., et al. Nonmetastatic osteosarcoma of the extremity with pathologic fracture at presentation: local and systemic control by amputation or limb salvage after preoperative chemotherapy. Acta Orthop Scand 2003, 74:449-454.
51. Salunke A.A., Chen Y., Tan J.H., et al. Does a pathological fracture affect the prognosis in patients with osteosarcoma of the extremities?. Bone Joint J 2014, 96-B:1396-1403.
52. Sun L., Li Y., Zhang J., et al. Prognostic value of pathologic fracture in patients with high grade localized osteosarcoma: a systemic review and meta-analysis of cohort studies. J Orthop Res 2015, 33:131-139.
53. Mattei P. Surgery for metastatic disease. Curr Opin Pediatr 2013, 25:362-367.
54. Janeway K.A., Grier H.E. Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects. Lancet Oncol 2010, 11:670-678.
55. Lee J.S., DuBois S.G., Boscardin W.J., et al. Secondary malignant neoplasms among children, adolescents, and young adults with osteosarcoma. Cancer 2014, 120:3987-3993.
56. Fidler M.M., Frobisher C., Guha J., et al. Long-term adverse outcomes in survivors of childhood bone sarcoma: the British Childhood Cancer Survivor Study. Br J Cancer 2015, 112:1857-1865.
57. Ghert M., Deheshi B., Holt G., et al. Prophylactic antibiotic regimens in tumour surgery (PARITY): protocol for a multicentre randomised controlled study. BMJ Open 2012, 2. [pii:e002197].
58. Meyers P.A., Schwartz C.L., Krailo M.D., et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival-a report from the Children's Oncology Group. J Clin Oncol 2008, 26:633-638.
59. Rivera-Valentin R.K., Zhu L., Hughes D.P.M. Bone sarcomas in pediatrics: progress in our understanding of tumor biology and implications for therapy. Pediatr Drugs 2015, 17(4):257-271.
60. Kansara M., Teng M.W., Smyth M.J., et al. Translational biology of osteosarcoma. Nat Rev Cancer 2014, 14:722-735.